Mouse Anti-DCK Recombinant Antibody (CBYCD-179) (CBMAB-D0350-YC)

Yoshida, K., Fujita, A., Narazaki, H., Asano, T., & Itoh, Y. (2022). Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms. Cancer chemotherapy and pharmacology, 89(1), 83-91.

Carlini, F., Ivaldi, F., Gualandi, F., Boschert, U., Centonze, D., Matarese, G., ... & Uccelli, A. (2021). Different susceptibility of T and B cells to cladribine depends on their levels of deoxycytidine kinase activity linked to activation status. Journal of Neuroimmune Pharmacology, 1-11.

Wu, B., Mao, Z. J., Wang, Z., Wu, P., Huang, H., Zhao, W., ... & Yin, B. (2021). Deoxycytidine kinase (DCK) mutations in human acute myeloid leukemia resistant to Cytarabine. Acta Haematologica, 144(5), 534-541.

Hosokawa, M., Seiki, R., Iwakawa, S., & Ogawara, K. I. (2021). Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase. Biochemical and Biophysical Research Communications, 578, 157-162.

Jaramillo, A. C., Bergman, A. M., Comijn, E. M., Jansen, G., Kaspers, G. J., Cloos, J., & Peters, G. J. (2020). Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase. Nucleosides, Nucleotides & Nucleic Acids, 39(10-12), 1346-1346.

Vena, F., Bayle, S., Nieto, A., Quereda, V., Aceti, M., Frydman, S. M., ... & Duckett, D. (2020). Targeting casein kinase 1 delta sensitizes pancreatic and bladder cancer cells to gemcitabine treatment by upregulating deoxycytidine kinase. Molecular cancer therapeutics, 19(8), 1623-1635.

Sun, X., Xu, X., Chen, Y., Guan, R., Cheng, T., Wang, Y., ... & Hang, T. (2019). Danggui buxue decoction sensitizes the response of non-small-cell lung cancer to gemcitabine via regulating deoxycytidine kinase and P-glycoprotein. Molecules, 24(10), 2011.

Han, Z., Li, Y., Zhang, J., Liu, J., Chen, C., Van Zijl, P. C., & Liu, G. (2019). Molecular imaging of deoxycytidine kinase activity using deoxycytidine-enhanced CEST MRI. Cancer research, 79(10), 2775-2783.

Hellendahl, K. F., Kamel, S., Wetterwald, A., Neubauer, P., & Wagner, A. (2019). Human deoxycytidine kinase is a valuable biocatalyst for the synthesis of nucleotide analogues. Catalysts, 9(12), 997.

Huang, M., Inukai, T., Miyake, K., Tanaka, Y., Kagami, K., Abe, M., ... & Sugita, K. (2018). Clofarabine exerts antileukemic activity against cytarabine‐resistant B‐cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression. Cancer medicine, 7(4), 1297-1316.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-DCK Recombinant Antibody (D0343)

Mouse Anti-DCK Recombinant Antibody (1G6)

Mouse Anti-DCK Recombinant Antibody (2F10)

Mouse Anti-DCK Recombinant Antibody (3G10)

Mouse Anti-DCK Recombinant Antibody (CBYCD-180)

Mouse Anti-DCK Recombinant Antibody (D0345)

Mouse Anti-DCK Recombinant Antibody (3E4)

Mouse Anti-DCK Recombinant Antibody (1E7)

Mouse Anti-DCK Recombinant Antibody (D0341)

Mouse Anti-DCK Recombinant Antibody (4H3)

Isotype control